Codex DNA, founded in 2011, is a biotechnology company focused on advancing the synthetic biology market. With its slogan, "Innovative synthetic biology technologies enabling rapid, accurate DNA synthesis for academic and commercial research," the company emphasizes its commitment to facilitating expedited DNA synthesis.
Codex DNA provides sophisticated hardware, software, materials, and methodologies designed to streamline DNA synthesis processes. By catering to both academic and commercial researchers, it offers solutions that notably reduce the turnaround time associated with gene synthesis workflows.
Its business model centers around the sale of these groundbreaking gene synthesis technologies and supplementary services. The company entered the public market with a successful $122.70 million IPO on 01 June 2021, marking a significant milestone in its growth trajectory. This positioning within the Biotechnology industry highlights its potential for delivering long-term value to investors eager to capitalize on advancements in synthetic biology.
